The proportional treatment effect: A metric that empowers and connects

Clinical trials with continuous endpoints evaluate efficacy by comparing the difference in mean changes from baseline between groups. However, clinicians often interpret results in terms of a proportional reduction rather than an absolute difference. An alternative approach is to reparametrize this difference as a proportional treatment effect (PTE), calculated by dividing the difference by the placebo mean change. PTE is not a new metric per se, but a specific reparameterization gaining traction in certain clinical contexts. We demonstrate that, in theory, PTE can be more powerful than the simple difference in means while still controlling the type I error rate. This is achieved using the delta method, as implemented in well-established computational tools like the R package 'msm' and the SAS procedure 'NLMIXED'. By analyzing data from phase III trials, we illustrate how a PTE connects treatment outcomes across various endpoints and different presentation formats. The availability of these well-established statistical tools for estimating proportional treatment effects, combined with this theoretical demonstration, suggests an alternative test statistic for clinical trials with continuous endpoints.

Authors

Institutions

Publication Details

Journal
Journal of Biopharmaceutical Statistics
Published
2025-12-19
DOI
https://doi.org/10.1080/10543406.2025.2602479
Primary Topic
Statistical Methods in Clinical Trials
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

The proportional treatment effect: A metric that empowers and connects

Gary Cutter, Caiyan Li, Yan Li, Kun Jin et al.
Journal of Biopharmaceutical Statistics
Statistical Methods in Clinical Trials
article

The proportional treatment effect: A metric that empowers and connects

Gary Cutter, Caiyan Li, Yan Li, Kun Jin, Guoqiao Wang, Yijie Liao
article en

Abstract

Clinical trials with continuous endpoints evaluate efficacy by comparing the difference in mean changes from baseline between groups. However, clinicians often interpret results in terms of a proportional reduction rather than an absolute difference. An alternative approach is to reparametrize this difference as a proportional treatment effect (PTE), calculated by dividing the difference by the placebo mean change. PTE is not a new metric per se, but a specific reparameterization gaining traction in certain clinical contexts. We demonstrate that, in theory, PTE can be more powerful than the simple difference in means while still controlling the type I error rate. This is achieved using the delta method, as implemented in well-established computational tools like the R package 'msm' and the SAS procedure 'NLMIXED'. By analyzing data from phase III trials, we illustrate how a PTE connects treatment outcomes across various endpoints and different presentation formats. The availability of these well-established statistical tools for estimating proportional treatment effects, combined with this theoretical demonstration, suggests an alternative test statistic for clinical trials with continuous endpoints.

Journal of Biopharmaceutical Statistics
Washington University in St. Louis (US), University of Alabama at Birmingham (US), Allogene Therapeutics (United States) (US), Klogene (United States) (US), Alector (United States) (US)
Openalex Percentile: Top 62%
Statistical Methods in Clinical Trials
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.